Carruthers Jean, Carruthers Alastair
Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, BC, Canada.
J Cosmet Laser Ther. 2007 Sep;9(3):186-92. doi: 10.1080/14764170701411470.
Very few pharmaceutical preparations share an evolutionary history as remarkable as that of botulinum neurotoxin (BoNT). The exotoxin of the organism Clostridium botulinum, once feared as a terrible poison, has been reborn as a highly regarded and widely used therapeutic and aesthetic agent. In less than two decades since the report of the success of BoNT type A (BoNTA) in reducing glabellar lines, injection of this product has become the most common non-surgical cosmetic procedure performed in the USA and worldwide. In addition to temporarily eliminating rhytids by muscle weakening, other dermatologic applications of BoNTA include correcting facial asymmetries and treating hyperhidrosis. Although BOTOX is the most clinically substantiated and published of the BoNTA preparations, other BoNTA products, as well as a BoNT type B product, are available in some parts of the world, and others are in development.
很少有药物制剂的进化史能像肉毒杆菌神经毒素（BoNT）那样引人注目。肉毒梭菌的外毒素，曾被视为可怕的毒药，如今已重生为备受推崇且广泛应用的治疗和美容药物。自A型肉毒杆菌毒素（BoNTA）成功减少眉间纹的报告发表以来，在不到二十年的时间里，注射该产品已成为美国乃至全球最常见的非手术美容程序。除了通过削弱肌肉来暂时消除皱纹外，BoNTA在皮肤科的其他应用还包括矫正面部不对称和治疗多汗症。尽管保妥适（BOTOX）是临床证据最充分且发表文献最多的BoNTA制剂，但在世界某些地区也有其他BoNTA产品以及一种B型肉毒杆菌毒素产品可供使用，还有其他产品正在研发中。
